TScan Therapeutics (TCRX) Cash from Financing Activities (2020 - 2025)
TScan Therapeutics (TCRX) posted quarterly Cash from Financing Activities of $73000.0 for Q4 2025, down 99.84% year-over-year from $45.7 million in Q4 2024, and down 37.07% quarter-over-quarter from $116000.0 in Q2 2025.
TScan Therapeutics (TCRX) Cash from Financing Activities (2020 - 2025) Analysis & Trends
TScan Therapeutics (TCRX) has reported Cash from Financing Activities for 6 consecutive years, with $73000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 99.84% year-over-year to $73000.0; the TTM figure through Dec 2025 stood at -$336000.0 (down 100.16% YoY), while the FY2025 annual figure was -$336000.0, down 100.16% from the prior year.
- Cash from Financing Activities declined to $73000.0 in Q4 2025 per TCRX's latest filing, from $116000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $161.6 million in Q2 2024 and bottomed at -$686000.0 in Q2 2021.
- Historically, Cash from Financing Activities has averaged $25.1 million across 5 years, with a median of $116000.0 in 2025.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities soared 9060700.0% — and 2025, when it tumbled 303.49%.
- TScan Therapeutics' Cash from Financing Activities stood at $120000.0 in 2021, then declined by 10.0% to $108000.0 in 2022, then tumbled by 82.41% to $19000.0 in 2023, then soared by 240373.68% to $45.7 million in 2024, then sank by 99.84% to $73000.0 in 2025.
- Business Quant data shows TCRX's Cash from Financing Activities at $73000.0 in Q4 2025, $116000.0 in Q2 2025, and -$525000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 73,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Jun 30, 2025 | 116,000.00 |
| Jun 30, 2025 | 116,000.00 |
| Mar 31, 2025 | -525,000.00 |
| Mar 31, 2025 | -525,000.00 |
| Dec 31, 2024 | 45.69 Mn |
| Dec 31, 2024 | 45.69 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Jun 30, 2024 | 161.59 Mn |
| Jun 30, 2024 | 161.59 Mn |
| Mar 31, 2024 | 258,000.00 |
| Mar 31, 2024 | 258,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Sep 30, 2023 | -252,000.00 |
| Sep 30, 2023 | -252,000.00 |
| Dec 31, 2022 | 108,000.00 |
| Dec 31, 2022 | 108,000.00 |